At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 6, 2026 at 09:45 ET
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 4,871,850 shares of Hemab Therapeutics (COAG), representing 10.4% of outstanding common stock as of October 30, 2026. This is a routine passive stake update; no prior FMR 13G is in the provided context for comparison, so the direction of change is unknown.
- FMR LLC (Fidelity) filed an amended Schedule 13G for Hemab Therapeutics Holdings, Inc. (COAG).
- Beneficial ownership: 4,871,850 shares of common stock, representing 10.4% of outstanding shares as of October 30, 2026.
- Fidelity Management & Research Company LLC is the entity that beneficially owns 5% or greater of the outstanding shares.
- The filing is a passive investment disclosure under Rule 13d-1(b); FMR certifies the shares were not acquired to change or influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access